^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | sapanisertib (CB-228) (mTORC1 inhibitor, mTORC2 inhibitor) + telaglenastat (CB-839) (Glutaminase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MA13.08 - A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients With Advanced NSCLC (NCI 10327): Results from Dose Escalation
Published date:
07/12/2022
Excerpt:
Of the 8 patients evaluable for response (1 PR/4 SD/3 PD), 5 patients had tumor shrinkage including a patient with KRAS/KEAP1 mutant LUAD (SD) and 1 patient with LUSC harboring an NFE2L2 mutation (PR) at DL2. The RED for sapanisertib + telaglenastat is DL1 (sapanisertib 2mg po qd, telaglenastat 800mg po bid). The majority of evaluable patients had tumor shrinkage including a PR in a patient with LUSC harboring an NFE2L2 mutation. Sapanisertib and telaglenastat is safe and tolerable at the RED.
Trial ID:
